Inside informationEnglish
Press Release: Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Sanofi
- Filed
- 08/04/2025, 19:10
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 119128_20250408